Time to Optimize Deescalation Strategies in Triple-Negative Breast Cancer?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36083131.
- Also identified by DOI 10.1158/1078-0432.CCR-22-2140.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pathologic response serves as a tool to optimize escalation and deescalation of adjuvant treatment. Neoadjuvant carboplatin-taxane combination is a promising chemotherapy deescalation strategy for triple-negative breast cancer. Many key points, such as trial design/patient selection, response biomarkers, role of immunotherapy, and patient advocate input, will have to be carefully considered in order to advance neoadjuvant chemotherapy deescalation investigations. See related article by Gluz et al., p. 4995.
Medical subject headings
- Neoadjuvant Therapy
- Triple Negative Breast Neoplasms